MCID: WLL004
MIFTS: 39

Wallerian Degeneration

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Wallerian Degeneration

MalaCards integrated aliases for Wallerian Degeneration:

Name: Wallerian Degeneration 52 54 71
Wallerian Degeneration of the Pyramidal Tract 52

Classifications:



External Ids:

UMLS 71 C0043020

Summaries for Wallerian Degeneration

MalaCards based summary : Wallerian Degeneration, also known as wallerian degeneration of the pyramidal tract, is related to neuritis and peripheral nervous system disease. An important gene associated with Wallerian Degeneration is NMNAT1 (Nicotinamide Nucleotide Adenylyltransferase 1), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Nitrous oxide and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Wallerian degeneration is an active process of degeneration that results when a nerve fiber is cut or... more...

Related Diseases for Wallerian Degeneration

Diseases related to Wallerian Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 neuritis 30.1 MPZ MAG CNTF
2 peripheral nervous system disease 29.7 VEGFA MPZ MAG CNTF
3 hereditary neuropathies 29.6 MPZ MAG
4 charcot-marie-tooth disease 29.0 NEFM MPZ MAG ERBB2 CNTF
5 motor neuron disease 28.9 VEGFA NEFM MAG CNTF
6 spinal cord injury 10.6
7 neuropathy 10.5
8 cerebrovascular disease 10.5
9 stroke, ischemic 10.4
10 middle cerebral artery infarction 10.4
11 cytokine deficiency 10.4
12 brain injury 10.4
13 multiple sclerosis 10.3
14 traumatic brain injury 10.3
15 hydrops, lactic acidosis, and sideroblastic anemia 10.2
16 hemiplegia 10.2
17 relapsing-remitting multiple sclerosis 10.2
18 ischemia 10.2
19 bullous retinoschisis 10.2 VEGFA SARM1
20 amyotrophic lateral sclerosis 1 10.2
21 supranuclear palsy, progressive, 1 10.2
22 tooth disease 10.2
23 mononeuropathy 10.2
24 spinal muscular atrophy 10.2
25 retinal ischemia 10.2
26 guillain-barre syndrome 10.2
27 lateral sclerosis 10.2
28 temporal lobe epilepsy 10.2
29 scrapie 10.2
30 muscular atrophy 10.2
31 48,xyyy 10.2
32 argyria 10.2
33 primary peritoneal carcinoma 10.1 VEGFA ERBB2
34 autoimmune peripheral neuropathy 10.1 MPZ MAG
35 osteosclerotic myeloma 10.0 VEGFA MAG
36 autoimmune neuropathy 10.0 MPZ MAG
37 gastroesophageal junction adenocarcinoma 10.0 VEGFA ERBB2
38 alzheimer disease 10.0
39 charcot-marie-tooth disease, demyelinating, type 1a 10.0
40 creutzfeldt-jakob disease 10.0
41 huntington disease 10.0
42 hypercholesterolemia, familial, 1 10.0
43 neuropathy, hereditary, with liability to pressure palsies 10.0
44 ocular dominance 10.0
45 polykaryocytosis inducer 10.0
46 triiodothyronine receptor auxiliary protein 10.0
47 krabbe disease 10.0
48 sudanophilic cerebral sclerosis 10.0
49 adrenoleukodystrophy 10.0
50 ataxia and polyneuropathy, adult-onset 10.0

Graphical network of the top 20 diseases related to Wallerian Degeneration:



Diseases related to Wallerian Degeneration

Symptoms & Phenotypes for Wallerian Degeneration

GenomeRNAi Phenotypes related to Wallerian Degeneration according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.53 UBE4B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.53 CNTF
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.53 CNTF ERBB2 SEMA3A UBE4B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 9.53 CNTF
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.53 UBE4B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.53 UBE4B
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.53 CNTF
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.53 CNTF SEMA3A
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.53 SEMA3A
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.53 SEMA3A
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.53 ERBB2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.53 CNTF
13 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 ERBB2 NRP2 SEMA3A SEMA3F VEGFA

MGI Mouse Phenotypes related to Wallerian Degeneration:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 CLU CNTF ERBB2 MAG MPZ NMNAT1
2 cellular MP:0005384 9.97 CNTF ERBB2 MPZ NMNAT1 NMNAT2 NRP2
3 muscle MP:0005369 9.5 CLU CNTF ERBB2 NMNAT2 NRP2 UBE4B
4 nervous system MP:0003631 9.5 CLU CNTF ERBB2 MAG MPZ NMNAT1

Drugs & Therapeutics for Wallerian Degeneration

Drugs for Wallerian Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Choline Approved, Nutraceutical Phase 4 62-49-7 305
6 Nootropic Agents Phase 4
7 Cytidine Diphosphate Choline Phase 4
8 Anesthetics Phase 4
9 Central Nervous System Depressants Phase 4
10 Neurotransmitter Agents Phase 4
11 Anesthetics, Local Phase 4
12 Sympathomimetics Phase 4
13 Adrenergic Agonists Phase 4
14 Epinephryl borate Phase 4
15 Respiratory System Agents Phase 4
16 Anti-Asthmatic Agents Phase 4
17 Vasoconstrictor Agents Phase 4
18 Adrenergic beta-Agonists Phase 4
19 Autonomic Agents Phase 4
20 Bronchodilator Agents Phase 4
21 Mydriatics Phase 4
22 Adrenergic Agents Phase 4
23
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
26 Micronutrients Phase 2
27 Vitamins Phase 2
28 Trace Elements Phase 2
29 Hypolipidemic Agents Phase 2
30 Vitamin B Complex Phase 2
31 Vitamin B3 Phase 2
32 Nutrients Phase 2
33 Vasodilator Agents Phase 2
34 Vitamin B9 Phase 2
35 Folate Phase 2
36 Lipid Regulating Agents Phase 2
37 Nicotinic Acids Phase 2
38 Antimetabolites Phase 2
39 Pharmaceutical Solutions Phase 1
40 Calamus
41 PK 11195 85532-75-8
42 Analgesics, Non-Narcotic
43 Anesthetics, General
44 Anesthetics, Inhalation
45 Analgesics

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
2 Intercostal Cryoneurolysis Following Traumatic Rib Fractures Enrolling by invitation NCT04198662 Phase 4 Intercostal nerve block ropivacaine with epinephrine
3 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration Not yet recruiting NCT03912220 Phase 2 Nicotinamide riboside;Placebo Oral Tablet
4 Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function Recruiting NCT02359825 Phase 1 Polyethylene glycol (PEG)
5 A Post-Market, Prospective, Randomized, Controlled Study to Evaluate the Iovera° Device Completed NCT03327220
6 FOCAL CORTICAL ATROPHY AFTER MYOCARDIAL INTERNAL CAPSULE: CORRELATION FRACTION ANISOTROPY BEAM PYRAMID AND DISABILITY Completed NCT01862172
7 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
8 Effectiveness of Preoperative Cryoneurolysis (Iovera) for Postoperative Pain Control in Total Knee Arthroplasty Recruiting NCT03818022
9 TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort Recruiting NCT03662750
10 Measuring Active Microglia in Progressive Multiple Sclerosis Active, not recruiting NCT02207075
11 Intercostal Cryoneurolysis Following Traumatic Rib Fractures Enrolling by invitation NCT03917823
12 Cryoneurolysis of Arnold's Nerve and Follow-up by Tractography: Feasibility Study Not yet recruiting NCT03735914
13 Cryoneurolysis for the Management of Chronic Pain in Patients With Knee Osteoarthritis; A Randomized Controlled Study Not yet recruiting NCT03774121
14 New Clinical Magnetic Resonance Technologies for Capturing Brain Microstructure Alterations in Patients With Minor Stroke or Transient Ischemic Attack Not yet recruiting NCT04118790

Search NIH Clinical Center for Wallerian Degeneration

Genetic Tests for Wallerian Degeneration

Anatomical Context for Wallerian Degeneration

MalaCards organs/tissues related to Wallerian Degeneration:

40
Spinal Cord, Brain, Bone, Cortex, Dorsal Root Ganglion, Bone Marrow, T Cells

Publications for Wallerian Degeneration

Articles related to Wallerian Degeneration:

(show top 50) (show all 2144)
# Title Authors PMID Year
1
Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. 54 61
20126265 2010
2
Protection of vincristine-induced neuropathy by WldS expression and the independence of the activity of Nmnat1. 54 61
17113230 2007
3
Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord. 54 61
15634734 2005
4
Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. 54 61
9633807 1998
5
Central neuron-glial and glial-glial interactions following axon injury. 54 61
9602498 1998
6
Nerve expansion in nerve regeneration: effect of time on induction of ornithine decarboxylase and Schwann cell proliferation. 54 61
9324090 1997
7
Transient expression of the neurofilament proteins NF-L and NF-M by Schwann cells is regulated by axonal contact. 54 61
9373038 1997
8
Role of ornithine decarboxylase in proliferation of Schwann cells during Wallerian degeneration and its enhancement by nerve expansion. 54 61
7565936 1995
9
Temporal and spatial expression of ciliary neurotrophic factor after peripheral nerve injury. 54 61
8339774 1993
10
Expression of recombinant myelin-associated glycoprotein in primary Schwann cells promotes the initial investment of axons by myelinating Schwann cells. 54 61
1697293 1990
11
Protein microarray analysis of cytokine expression changes in distal stumps after sciatic nerve transection. 61
31571662 2020
12
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. 61
31740269 2020
13
Different protein expression patterns in rat spinal nerves during Wallerian degeneration assessed using isobaric tags for relative and absolute quantitation proteomics profiling. 61
31552905 2020
14
Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases. 61
31761689 2020
15
Successful and Complete Recovery of the Ulnar Nerve After Eight Years of Chronic Injury Through Local Steroid Injections: A Case Report. 61
31900814 2020
16
Radiation induced Wallerian degeneration of corticospinal tract in a case of brain tumour. 61
31954053 2020
17
Wallerian Degeneration of the Cerebral Peduncle and Association with Motor Outcome in Childhood Stroke. 61
31607421 2020
18
Collapsin response mediator protein 4 (CRMP4) facilitates Wallerian degeneration and axon regeneration following sciatic nerve injury. 61
32001550 2020
19
Prostaglandin D2 synthase modulates macrophage activity and accumulation in injured peripheral nerves. 61
31479164 2020
20
Histological and ultrastructural study of AflatoxinB1 induced neurotoxicity in Sciatic nerve of adult male Albino rats. 61
31893473 2020
21
Magnetic resonance imaging evaluation of Wallerian degeneration of bilateral middle cerebellar peduncles after pontine infarction. 61
31828281 2019
22
Differential gene and protein expression between rat tibial nerve and common peroneal nerve during Wallerian degeneration. 61
31397358 2019
23
Wallerian degeneration as a therapeutic target in traumatic brain injury. 61
31633494 2019
24
Examination of the human motor endplate after brachial plexus injury with two-photon microscopy. 61
31820462 2019
25
Deletion of SIRPα (signal regulatory protein-α) promotes phagocytic clearance of myelin debris in Wallerian degeneration, axon regeneration, and recovery from nerve injury. 61
31883525 2019
26
Histological validation of per-bundle water diffusion metrics within a region of fiber crossing following axonal degeneration. 61
31326575 2019
27
Peripheral Nerve Injuries: Electrophysiology for the Neurosurgeon. 61
31857526 2019
28
Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia. 61
31132363 2019
29
Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. 61
31661035 2019
30
Severe biallelic loss-of-function mutations in nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) in two fetuses with fetal akinesia deformation sequence. 61
31136762 2019
31
FGF9 alters the Wallerian degeneration process by inhibiting Schwann cell transformation and accelerating macrophage infiltration. 61
31220553 2019
32
Altered mitochondrial bioenergetics are responsible for the delay in Wallerian degeneration observed in neonatal mice. 61
31176719 2019
33
Combined hypertrophic olivary degeneration and Wallerian degeneration of the bilateral middle cerebellar peduncles: a case report. 61
30941625 2019
34
Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. 61
31484833 2019
35
Extra-axonal restricted diffusion as an in-vivo marker of reactive microglia. 61
31554896 2019
36
Histological, electrophysiological and clinical effects of thermal radiofrequency therapy of the saphenous nerve and pulsed radiofrequency therapy of the sciatic nerve in dogs. 61
31358392 2019
37
Axon death signalling in Wallerian degeneration among species and in disease. 61
31455157 2019
38
Mechanisms of injury-induced axon degeneration. 61
31071521 2019
39
NAD+ cleavage activity by animal and plant TIR domains in cell death pathways. 61
31439792 2019
40
Inhibition of Neuronal Nitric Oxide Synthase by Ethyl Pyruvate in Schwann Cells Protects Against Peripheral Nerve Degeneration. 61
31218567 2019
41
Genetic inhibition of CRMP2 phosphorylation delays Wallerian degeneration after optic nerve injury. 61
31097218 2019
42
p75 and neural cell adhesion molecule 1 can identify pathologic Schwann cells in peripheral neuropathies. 61
31353867 2019
43
Effect of exogenous spastin combined with polyethylene glycol on sciatic nerve injury. 61
30804259 2019
44
Wallerian degeneration in experimental focal cortical ischemia. 61
31051228 2019
45
Validation of targeted microsurgical spermatic cord denervation: comparison of outcomes to traditional complete microsurgical spermatic cord denervation. 61
30416135 2019
46
Percutaneous Neurolysis for Pain Management in Oncological Patients. 61
30783779 2019
47
CD56+ B-cell Neurolymphomatosis in a Cat. 61
31159947 2019
48
PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases. 61
31139952 2019
49
The Role of Vitamin B12 in the Management and Optimization of Treatment in Patients With Degenerative Cervical Myelopathy. 61
31192102 2019
50
Plasticity in Adult Mouse Visual Cortex Following Optic Nerve Injury. 61
30668659 2019

Variations for Wallerian Degeneration

Expression for Wallerian Degeneration

Search GEO for disease gene expression data for Wallerian Degeneration.

Pathways for Wallerian Degeneration

Pathways related to Wallerian Degeneration according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 NRP2 NEFM MAG CLU
2 10.7 VEGFA NEFM CNTF

GO Terms for Wallerian Degeneration

Cellular components related to Wallerian Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.43 SEMA3A SARM1 NRP2 NMNAT2 NEFM CNTF
2 paranode region of axon GO:0033270 9.32 SIRT2 MAG
3 Schmidt-Lanterman incisure GO:0043220 9.26 SIRT2 MAG
4 neurofibrillary tangle GO:0097418 9.16 NEFM CLU
5 myelin sheath GO:0043209 8.92 SIRT2 MPZ MAG ERBB2

Biological processes related to Wallerian Degeneration according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.09 VEGFA SIRT2 SEMA3A SARM1 NRP2 CNTF
2 neural crest cell migration GO:0001755 9.72 SEMA3F SEMA3A NRP2
3 negative chemotaxis GO:0050919 9.71 SEMA3F SEMA3A NRP2
4 semaphorin-plexin signaling pathway GO:0071526 9.7 SEMA3F SEMA3A NRP2
5 negative regulation of axon extension GO:0030517 9.65 SEMA3A MAG
6 nerve development GO:0021675 9.65 SEMA3F SEMA3A NRP2
7 regulation of neuron death GO:1901214 9.64 SARM1 CLU
8 regulation of postsynapse organization GO:0099175 9.64 SEMA3F NRP2
9 nucleotide biosynthetic process GO:0009165 9.63 NMNAT2 NMNAT1
10 vascular endothelial growth factor signaling pathway GO:0038084 9.63 VEGFA NRP2
11 sympathetic ganglion development GO:0061549 9.63 SEMA3F SEMA3A NRP2
12 NAD metabolic process GO:0019674 9.62 NMNAT2 NMNAT1
13 NAD biosynthetic process GO:0009435 9.61 NMNAT2 NMNAT1
14 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.61 MPZ MAG
15 facial nerve structural organization GO:0021612 9.61 SEMA3F SEMA3A NRP2
16 semaphorin-plexin signaling pathway involved in axon guidance GO:1902287 9.6 SEMA3F SEMA3A
17 pyridine nucleotide biosynthetic process GO:0019363 9.59 NMNAT2 NMNAT1
18 axonogenesis involved in innervation GO:0060385 9.58 SEMA3A NPTX1
19 branchiomotor neuron axon guidance GO:0021785 9.58 SEMA3F SEMA3A
20 axon extension involved in axon guidance GO:0048846 9.58 SEMA3F SEMA3A NRP2
21 trigeminal ganglion development GO:0061551 9.57 SEMA3A NRP2
22 trigeminal nerve structural organization GO:0021637 9.56 SEMA3F SEMA3A
23 neural crest cell migration involved in autonomic nervous system development GO:1901166 9.54 SEMA3F SEMA3A NRP2
24 facioacoustic ganglion development GO:1903375 9.51 SEMA3A NRP2
25 semaphorin-plexin signaling pathway involved in neuron projection guidance GO:1902285 9.5 SEMA3F SEMA3A NRP2
26 gonadotrophin-releasing hormone neuronal migration to the hypothalamus GO:0021828 9.49 SEMA3A NRP2
27 sympathetic neuron projection guidance GO:0097491 9.43 SEMA3F SEMA3A NRP2
28 sympathetic neuron projection extension GO:0097490 9.33 SEMA3F SEMA3A NRP2
29 nervous system development GO:0007399 9.23 VEGFA SIRT2 SEMA3A SARM1 NRP2 MAG
30 ventral trunk neural crest cell migration GO:0036486 9.13 SEMA3F SEMA3A NRP2

Molecular functions related to Wallerian Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nicotinate-nucleotide adenylyltransferase activity GO:0004515 8.96 NMNAT2 NMNAT1
2 nicotinamide-nucleotide adenylyltransferase activity GO:0000309 8.62 NMNAT2 NMNAT1

Sources for Wallerian Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....